Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition ...

One of the world’s biggest genetic databases comprises DNA data donated over the years by more than a million retired ...

Momentum in Johnson & Johnson’s cardiovascular business continues, while the company looks to regain its footing in the ...

Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor ...

The artificial intelligence-powered spine surgery developer Carlsmed is showing some backbone as it kicks off its IPO, with ...

The National Institutes of Health (NIH) has fired its chief operating officer amid a probe into whether his wife could have ...

Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

A pair of CROs from opposite sides of the Atlantic Ocean are merging to form a global organization. | A pair of CROs from ...

The Department of Health and Human Services (HHS) is laying off certain employees that were notified months ago of the ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The FDA has lifted one of the two clinical holds placed on Kezar Life Sciences’ zetomipzomib, leading the biotech to speculate on whether to reignite another program for the same drug that remains ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...